CervoMed (NASDAQ:CRVO) Stock Rating Upgraded by Brookline Cap M

CervoMed (NASDAQ:CRVO) was upgraded by equities researchers at Brookline Cap M to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports. Brookline Cap M also issued estimates for CervoMed’s Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($2.65) EPS.

A number of other research analysts also recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of CervoMed in a report on Thursday, December 18th. They set an “overweight” rating on the stock. Roth Mkm set a $20.00 target price on CervoMed and gave the stock a “buy” rating in a report on Friday, October 17th. Zacks Research raised shares of CervoMed from a “strong sell” rating to a “hold” rating in a research report on Monday, January 12th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of CervoMed in a report on Thursday, December 18th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $31.00 target price on shares of CervoMed in a research note on Tuesday, December 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, CervoMed currently has an average rating of “Moderate Buy” and a consensus price target of $22.17.

CervoMed Trading Up 15.4%

CRVO stock traded up $0.71 during mid-day trading on Tuesday, hitting $5.31. The stock had a trading volume of 105,761 shares, compared to its average volume of 81,486. CervoMed has a 1-year low of $1.92 and a 1-year high of $16.94. The company has a fifty day moving average of $7.45 and a 200 day moving average of $8.16. The stock has a market capitalization of $49.13 million, a price-to-earnings ratio of -1.83 and a beta of -0.82.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings results on Friday, November 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). CervoMed had a negative net margin of 415.27% and a negative return on equity of 76.78%. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $1.43 million. As a group, sell-side analysts expect that CervoMed will post -1.88 earnings per share for the current fiscal year.

Insider Buying and Selling at CervoMed

In related news, CEO John J. Alam acquired 10,793 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was acquired at an average price of $8.46 per share, with a total value of $91,308.78. Following the completion of the transaction, the chief executive officer owned 12,500 shares of the company’s stock, valued at approximately $105,750. This represents a 632.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Sylvie Gregoire bought 10,807 shares of CervoMed stock in a transaction that occurred on Monday, November 17th. The stock was bought at an average price of $8.46 per share, with a total value of $91,427.22. Following the purchase, the director owned 12,500 shares of the company’s stock, valued at $105,750. This trade represents a 638.33% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 92,000 shares of company stock valued at $737,723 in the last ninety days. Company insiders own 35.40% of the company’s stock.

Hedge Funds Weigh In On CervoMed

Several large investors have recently added to or reduced their stakes in the company. Citizens Financial Group Inc. RI grew its holdings in shares of CervoMed by 23.0% during the 4th quarter. Citizens Financial Group Inc. RI now owns 37,477 shares of the company’s stock worth $296,000 after purchasing an additional 7,000 shares in the last quarter. Byrne Asset Management LLC bought a new position in CervoMed in the fourth quarter worth $116,000. Citadel Advisors LLC acquired a new stake in CervoMed during the third quarter worth $247,000. Two Sigma Investments LP bought a new stake in CervoMed in the 3rd quarter valued at $138,000. Finally, Readystate Asset Management LP bought a new stake in CervoMed in the 3rd quarter valued at $118,000. Institutional investors and hedge funds own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.